$200M Buyback Authorized, Doubling Down After $125M Program Wrapped
ZYME sits 45% above its 52-week low of $18.2.
Summary
Zymeworks' board authorized a second 2026 repurchase program of up to $200M, after fully completing the initial $125M program. Management expects to actually spend about $140M through 2028, funded from the balance sheet plus the $55M Roche upfront expected before year-end and a potential $100M TRELEGY ELLIPTA milestone in Q1 2027. At roughly $26 a share and 68.7M shares outstanding, the authorization covers a meaningful slice of the float, though the company retains full discretion on pace and can suspend it at any time. The buyback follows a strong stretch: FDA approval of Ziihera in first-line HER2+ GEA triggered a $250M Jazz milestone, Q3 revenue came in at $256.5M with $173.7M of net income, and the $929M Theravance acquisition closed in September. Watch HSR clearance for the Roche collaboration, which gates the $55M upfront and the start of repurchases before year-end.
At the time of this announcement, ZYME was trading at $26.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $18.20 to $31.97. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.